See more : B2 Impact ASA (B2I.OL) Income Statement Analysis – Financial Results
Complete financial analysis of AIkido Pharma Inc. (AIKI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of AIkido Pharma Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- DS Smith Plc (DITHF) Income Statement Analysis – Financial Results
- Right Tunnelling Public Company Limited (RT.BK) Income Statement Analysis – Financial Results
- APAC Resources Limited (1104.HK) Income Statement Analysis – Financial Results
- IG Group Holdings plc (IGGHY) Income Statement Analysis – Financial Results
- ZYNP Corporation (002448.SZ) Income Statement Analysis – Financial Results
AIkido Pharma Inc. (AIKI)
About AIkido Pharma Inc.
AIkido Pharma Inc., a biotechnology company, focuses on developing small-molecule anti-cancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2. It has license agreements with the University of Texas, University of Maryland Baltimore, Silo Pharma Inc., and Wake Forest University Health Sciences. The company was formerly known as Spherix Incorporated and changed its name to AIkido Pharma Inc. in March 2021. AIkido Pharma Inc. was founded in 1967 and is headquartered in New York, New York.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 | 1987 | 1986 | 1985 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 9.00K | 28.00K | 1.24M | 877.00K | 33.00K | 10.00K | 27.00K | 19.92K | 820.93K | 1.43M | 1.36M | 1.03M | 154.70K | 24.84M | 23.05M | 22.35M | 18.09M | 15.13M | 19.94M | 17.03M | 12.70M | 16.00M | 13.60M | 13.80M | 13.70M | 16.00M | 13.60M | 16.70M | 15.10M | 15.90M | 15.30M | 13.60M | 10.50M | 8.00M | 6.70M |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 81.00K | 92.00K | 84.00K | 88.00K | 864.00K | 3.00K | 0.00 | 388.07K | 517.68K | 449.29K | 397.65K | 54.29K | 20.79M | 17.93M | 17.36M | 12.60M | 11.55M | 13.64M | 11.09M | 9.60M | 12.50M | 9.90M | 9.60M | 9.90M | 12.90M | 10.40M | 13.20M | 12.40M | 13.30M | 12.90M | 11.10M | 7.70M | 5.90M | 5.20M |
| Gross Profit | 0.00 | 0.00 | 0.00 | 9.00K | -53.00K | 1.14M | 793.00K | -55.00K | -854.00K | 24.00K | 19.92K | 432.86K | 914.78K | 909.82K | 628.32K | 100.41K | 4.04M | 5.12M | 4.99M | 5.48M | 3.58M | 6.30M | 5.95M | 3.10M | 3.50M | 3.70M | 4.20M | 3.80M | 3.10M | 3.20M | 3.50M | 2.70M | 2.60M | 2.40M | 2.50M | 2.80M | 2.10M | 1.50M |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 100.00% | -189.29% | 92.56% | 90.42% | -166.67% | -8,540.00% | 88.89% | 100.00% | 52.73% | 63.86% | 66.94% | 61.24% | 64.90% | 16.28% | 22.21% | 22.31% | 30.32% | 23.66% | 31.59% | 34.91% | 24.41% | 21.88% | 27.21% | 30.43% | 27.74% | 19.38% | 23.53% | 20.96% | 17.88% | 16.35% | 15.69% | 18.38% | 26.67% | 26.25% | 22.39% |
| Research & Development | 830.00K | 559.00K | 2.49M | 2.52M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 10.00K | 727.09K | 1.65M | 4.85M | 6.83M | 4.00M | 5.87M | 883.61K | 288.11K | 196.36K | 423.17K | 476.00K | 390.16K | 281.08K | 300.00K | 400.00K | 600.00K | 600.00K | 500.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 11.68M | 7.73M | 4.06M | 0.00 | 3.06M | 3.69M | 4.58M | 5.13M | 20.79M | 15.07M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 11.68M | 7.73M | 4.06M | 3.17M | 3.06M | 3.69M | 4.58M | 5.13M | 20.79M | 15.07M | 2.76M | 3.13M | 4.08M | 3.27M | 3.14M | 3.87M | 5.64M | 5.14M | 5.36M | 5.83M | 4.51M | 4.03M | 3.94M | 3.70M | 3.80M | 2.80M | 2.50M | 2.30M | 2.70M | 2.00M | 1.90M | 2.10M | 2.30M | 2.30M | 1.60M | 1.30M | 1.20M | 1.10M |
| Other Expenses | 1.83M | 1.15M | 1.47M | 0.00 | 1.44M | 1.37M | 2.14M | 6.32M | 9.83M | 291.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.57M | 2.28M | 1.50M | 1.59M | 1.42M | 1.31M | 1.70M | 1.30M | 600.00K | 700.00K | 500.00K | 400.00K | 500.00K | 600.00K | 600.00K | 600.00K | 500.00K | 500.00K | 400.00K | 300.00K | 200.00K |
| Operating Expenses | 14.35M | 9.44M | 6.55M | 5.69M | 4.50M | 5.06M | 6.72M | 11.44M | 30.62M | 15.37M | 3.49M | 4.78M | 8.93M | 10.10M | 7.14M | 9.74M | 6.52M | 8.00M | 7.83M | 7.76M | 6.58M | 5.84M | 5.54M | 5.70M | 5.50M | 4.00M | 3.80M | 3.30M | 3.10M | 2.50M | 2.50M | 2.70M | 2.90M | 2.80M | 2.10M | 1.70M | 1.50M | 1.30M |
| Cost & Expenses | 14.35M | 9.44M | 6.55M | 5.69M | 4.50M | 5.06M | 6.72M | 11.44M | 30.62M | 15.37M | 3.49M | 5.17M | 9.44M | 10.55M | 7.54M | 9.79M | 27.32M | 25.93M | 25.19M | 20.36M | 18.13M | 19.48M | 16.62M | 15.30M | 18.00M | 13.90M | 13.40M | 13.20M | 16.00M | 12.90M | 15.70M | 15.10M | 16.20M | 15.70M | 13.20M | 9.40M | 7.40M | 6.50M |
| Interest Income | 687.00K | 252.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.46K | 6.11K | 37.65K | 348.44K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 7.76M | -2.27M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -2.00K | 2.22K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | -188.00K | 2.27M | -5.79M | 1.50M | 1.44M | 1.38M | 2.14M | 6.32M | 9.83M | 291.00K | 63.68K | 69.83K | 77.87K | 84.38K | 85.72K | 210.42K | 2.60M | 2.57M | 2.28M | 1.50M | 1.59M | 1.42M | 1.31M | 1.70M | 1.30M | 600.00K | 700.00K | 500.00K | 400.00K | 500.00K | 600.00K | 600.00K | 600.00K | 500.00K | 500.00K | 400.00K | 300.00K | 200.00K |
| EBITDA | -14.35M | -7.17M | -12.34M | -4.18M | 3.17M | -1.93M | -4.34M | -45.15M | -20.70M | -17.67M | -3.79M | -3.38M | -7.79M | -9.06M | -4.60M | -4.14M | 6.22M | -274.50K | -544.36K | -753.77K | -1.33M | 1.99M | 1.91M | -3.20M | -800.00K | 400.00K | 900.00K | 1.00M | 400.00K | -100.00K | 1.70M | 800.00K | 300.00K | 100.00K | 800.00K | 1.30M | 800.00K | 300.00K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | -46,477.78% | 11,321.43% | -156.15% | -494.64% | -136,809.09% | -207,010.00% | -65,459.26% | -19,041.00% | -411.41% | -543.93% | -666.93% | -448.40% | -2,673.58% | 25.04% | -1.19% | -2.44% | -4.17% | -8.78% | 9.99% | 11.19% | -25.20% | -5.00% | 2.94% | 6.52% | 7.30% | 2.50% | -0.74% | 10.18% | 5.30% | 1.89% | 0.65% | 5.88% | 12.38% | 10.00% | 4.48% |
| Operating Income | -14.35M | -9.44M | -6.55M | -5.69M | -6.87M | -3.82M | -8.55M | -52.01M | -30.61M | -15.35M | -3.47M | -4.35M | -8.01M | -9.19M | -6.51M | -9.64M | -2.48M | -2.89M | -2.85M | -2.27M | -3.00M | 453.77K | 411.05K | -2.60M | -2.00M | -300.00K | 400.00K | 500.00K | 0.00 | 700.00K | 1.00M | 200.00K | -300.00K | -400.00K | 400.00K | 1.10M | 600.00K | 200.00K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | -63,166.67% | -24,550.00% | -309.22% | -975.03% | -157,606.06% | -306,110.00% | -56,840.74% | -17,427.99% | -529.51% | -559.28% | -675.90% | -634.68% | -6,229.60% | -9.98% | -12.52% | -12.73% | -12.58% | -19.85% | 2.28% | 2.41% | -20.47% | -12.50% | -2.21% | 2.90% | 3.65% | 0.00% | 5.15% | 5.99% | 1.32% | -1.89% | -2.61% | 2.94% | 10.48% | 7.50% | 2.99% |
| Total Other Income/Expenses | -7.76M | 2.27M | -5.79M | 1.50M | 8.60M | 516.00K | 2.08M | 545.00K | 79.00K | -2.62M | 583.97K | 899.72K | 142.02K | 37.65K | 340.23K | 377.98K | 6.10M | 37.15K | 23.45K | 17.88K | 81.07K | 114.06K | 0.00 | -2.30M | -100.00K | 100.00K | -200.00K | 0.00 | 0.00 | -100.00K | 100.00K | 0.00 | -300.00K | -100.00K | -100.00K | -200.00K | -100.00K | 0.00 |
| Income Before Tax | -22.11M | -7.17M | -12.34M | -4.18M | 1.73M | -3.31M | -6.48M | -51.47M | -30.53M | -17.97M | -2.89M | -3.45M | -7.87M | -9.15M | -6.17M | -9.26M | 3.62M | -2.85M | -2.82M | -2.26M | -2.92M | 567.82K | 0.00 | -4.90M | -2.10M | -200.00K | 200.00K | 500.00K | 0.00 | 600.00K | 1.10M | 200.00K | -600.00K | -500.00K | 300.00K | 900.00K | 500.00K | 0.00 |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | -46,477.78% | 6,167.86% | -267.48% | -738.43% | -155,954.55% | -305,320.00% | -66,537.04% | -14,496.70% | -419.91% | -549.37% | -673.13% | -601.52% | -5,985.26% | 14.57% | -12.36% | -12.63% | -12.48% | -19.31% | 2.85% | 0.00% | -38.58% | -13.13% | -1.47% | 1.45% | 3.65% | 0.00% | 4.41% | 6.59% | 1.32% | -3.77% | -3.27% | 2.21% | 8.57% | 6.25% | 0.00% |
| Income Tax Expense | 7.76M | -2.27M | 0.00 | 0.00 | 8.60M | 516.00K | 2.08M | 545.00K | 79.00K | -2.62M | 583.97K | 14.49K | -133.19K | 37.65K | -552.80K | -3.41M | 105.05K | 37.15K | 23.45K | 17.88K | 81.12K | 114.06K | 0.00 | 300.00K | -100.00K | -100.00K | 100.00K | 100.00K | 100.00K | 200.00K | 400.00K | 100.00K | -200.00K | -200.00K | 100.00K | 400.00K | 200.00K | 0.00 |
| Net Income | -29.87M | -4.90M | -12.34M | -4.18M | 1.73M | -3.31M | -6.48M | -51.47M | -30.53M | -17.97M | -3.86M | -3.46M | -7.74M | -9.15M | -4.14M | -938.37K | 3.51M | -2.85M | -2.82M | -2.26M | -2.92M | 567.82K | 591.07K | -5.20M | -2.00M | -100.00K | 100.00K | 400.00K | -100.00K | -800.00K | 700.00K | 100.00K | -400.00K | -300.00K | 200.00K | 500.00K | 300.00K | 100.00K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | -46,477.78% | 6,167.86% | -267.48% | -738.43% | -155,954.55% | -305,320.00% | -66,537.04% | -19,360.63% | -421.68% | -540.07% | -673.13% | -403.09% | -606.58% | 14.14% | -12.36% | -12.63% | -12.48% | -19.31% | 2.85% | 3.47% | -40.94% | -12.50% | -0.74% | 0.72% | 2.92% | -0.63% | -5.88% | 4.19% | 0.66% | -2.52% | -1.96% | 1.47% | 4.76% | 3.75% | 1.49% |
| EPS | -5.60 | -2.97 | -7.47 | -28.31 | 15.48 | -43.13 | -126.45 | -2.20K | -2.12K | -18.73K | -19.38K | -36.06K | -117.22K | -147.56K | -79.53K | -18.05K | 70.26K | -63.31K | -64.14K | -53.73K | -71.27K | 14.56K | 15.16K | -148.57K | -60.61K | -3.13K | 3.45K | 13.79K | -3.57K | -28.57K | 25.00K | 3.57K | -14.29K | -10.71K | 7.14K | 17.86K | 10.71K | 3.57K |
| EPS Diluted | -5.60 | -2.97 | -7.47 | -28.31 | 15.48 | -43.13 | -121.90 | -2.20K | -2.12K | -18.73K | -19.38K | -36.06K | -117.22K | -147.56K | -79.53K | -18.05K | 70.26K | -63.31K | -64.14K | -53.73K | -71.27K | 14.56K | 15.16K | -148.57K | -60.61K | -3.13K | 3.45K | 13.79K | -3.57K | -28.57K | 25.00K | 3.57K | -14.29K | -10.71K | 7.14K | 17.86K | 10.71K | 3.57K |
| Weighted Avg Shares Out | 5.33M | 1.65M | 1.65M | 147.74K | 111.57K | 76.66K | 51.21K | 23.44K | 14.38K | 959.00 | 199.00 | 96.00 | 66.00 | 62.00 | 52.00 | 52.00 | 50.00 | 45.00 | 44.00 | 42.00 | 41.00 | 39.00 | 39.00 | 35.00 | 33.00 | 32.00 | 29.00 | 29.00 | 28.00 | 28.00 | 28.00 | 28.00 | 28.00 | 28.00 | 28.00 | 28.00 | 28.00 | 28.00 |
| Weighted Avg Shares Out (Dil) | 5.33M | 1.65M | 1.65M | 147.74K | 111.57K | 76.66K | 53.13K | 23.44K | 14.38K | 959.00 | 199.00 | 96.00 | 66.00 | 62.00 | 52.00 | 52.00 | 50.00 | 45.00 | 44.00 | 42.00 | 41.00 | 39.00 | 39.00 | 35.00 | 33.00 | 32.00 | 29.00 | 29.00 | 28.00 | 28.00 | 28.00 | 28.00 | 28.00 | 28.00 | 28.00 | 28.00 | 28.00 | 28.00 |
AIkido Pharma Inc. Announces Exercise of Option to Purchase Additional Shares in Bought Deal Offering
NEW YORK, Feb. 23, 2021 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced that the underwriter of its previously announced bought deal offering of common stock has partially exercised its option to purchase an additional...
Aikido Pharma Slumps On $75M Upsized Equity Offering Issued At 25% Discount
Aikido Pharma Inc (NASDAQ: AIKI) has increased the size of the previously announced public offering to 46.8 million shares at $1.60 per share, with gross proceeds of $75 million. The previous offering included 6.25 million shares for gross proceeds of a mere $10 million.
AIkido Pharma Inc. Increases Previously Announced Bought Deal Offering of Common Stock to $75 Million
NEW YORK, Feb. 16, 2021 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced that due to demand, the underwriter has agreed to increase the size of the previously announced public offering and purchase on a...
AIkido Pharma Inc. Announces $10 Million Bought Deal Offering Of Common Stock
NEW YORK, Feb. 16, 2021 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced that it has entered into an underwriting agreement with H.C. Wainwright & Co. under which the underwriter has agreed to purchase on...
Why Change Healthcare, Isoray And Alkido Are Moving Today
Alkido Pharma (NASDAQ: AIKI) shares are trading higher after the company announced it executed a Patent License Agreement for technology that covers the use of psilocybin for cancer applications. AIkido Pharma is engaged in the development of small-molecule anti-cancer therapeutics.
Aikido Pharma News: Why AIKI Stock Is Soaring Today
Shares of AIKI stock are skyrocketing after Aikido Pharma announced a new patent agreement for the use of psilocybin for cancer treatments. The post Aikido Pharma News: Why AIKI Stock Is Soaring Today appeared first on InvestorPlace.
AIkido Pharma Announces Publication of Artificial Intelligence-Machine Learning Sponsored Research Program for Pancreatic Cancer
NEW YORK, Dec. 9, 2020 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced the publication of positive results from its Artificial Intelligence/Machine Learning Sponsored Research Program in the field of Pancreatic Cancer. Pancreatic ductal...
AIkido Pharma Inc. Announces Results of 2020 Annual Stockholder Meeting
NEW YORK, Nov. 20, 2020 /PRNewswire/ -- AIkido Pharma Inc. (the "Company" or "AIkido") (NASDAQ: AIKI) today announced the results from the virtual 2020 Annual Meeting of Stockholders (the "Meeting") held on November 17, 2020 (the "Meeting"). All proposals that...
AIkido Pharma Inc. Provides Update on Its Next-Generation Chemotherapeutic Treatment DHA-dFdC
NEW YORK, Oct. 28, 2020 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today provided an update on its preclinical work on its next-generation chemotherapeutic, DHA-dFdC, and the solid lipid nanoparticle (SLN) drug delivery system to treat...
12 Healthcare Stocks Moving In Friday's After-Market Session
Gainers InVivo Therapeutics Hldg (NASDAQ:NVIV) shares rose 11.11% to $1.5 during Friday's after-market session. InVivo Therapeutics Hldg's trading volume hit 1.4K shares...
Source: https://incomestatements.info
Category: Stock Reports